IL-33 Depletion in COVID-19 Lungs

Authors :: Stanley J. Radio
Heather M. Strah
Kristina L. Bailey
Michael J. Duryee
John D. Dickinson
Ted R. Mikuls
Bryant R. England
Todd A. Wyatt
Amy Nelson
Jill A. Poole
Dawn M. Katafiasz
Daniel R. Anderson
Rohit Gaurav
Geoffrey M. Thiele
Debra J. Romberger
Source :: Chest
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Adult
Male
Pulmonary and Respiratory Medicine
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Myocytes, Smooth Muscle
Critical Care and Intensive Care Medicine
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
lung
Pulmonary Disease, Chronic Obstructive
Young Adult
IL-33, Interleukin-33
proSP-C, prosurfactant protein C
Research Letter
Humans
Vimentin
IPF, idiopathic pulmonary fibrosis
Medicine
Aged
Aged, 80 and over
SARS-CoV-2
business.industry
COVID-19
Endothelial Cells
Fibroblasts
Middle Aged
AEC2, type II alveolar epithelial cells
Interleukin-33
Pulmonary Surfactant-Associated Protein C
Virology
Idiopathic Pulmonary Fibrosis
Interleukin 33
COPD, chronic obstructive pulmonary disease
inflammation
Alveolar Epithelial Cells
Case-Control Studies
SARS-CoV2
IL-33
Female
Cardiology and Cardiovascular Medicine
business

Full Text Access

Tools